MGX Metagenomi Therapeutics, Inc.

NASDAQ
$1.10

Metagenomi Therapeutics, Inc. (MGX) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal Bullish Insiders bought more than they sold over this window — uncommon at any size.
Cluster activity 1 buyer in the last 30 days 1 buyer in the last 90 days 3 sellers in the last 90 days
Insiders buying
1
2 transactions
Insiders selling
3
6 transactions
Purchases
$23.4K
20,000 shares
Sales
$14.4K
11,588 shares
Net activity
$9.0K
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $14.4K 6 transactions · 11,588 shares

Largest single sale: $4.9K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: September 9, 2026 , by Reid Laurence .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Reid Laurence 2 fills Director Buy 20,000 $1.17 $23.4K 20,000
Irish Jian See Remarks Sell 2,140 $1.16 $2.5K 375,393 −0.6% of holding
Wapnick Pamela Chief Financial Officer Sell 1,911 $1.16 $2.2K 206,580 −0.9% of holding
Wein Matthew See Remarks Sell 358 $1.16 $415 126,133 −0.3% of holding
Irish Jian See Remarks Sell 3,737 $1.30 $4.9K 377,533 −1% of holding
Wapnick Pamela Chief Financial Officer Sell 2,884 $1.30 $3.7K 208,491 −1.4% of holding
Wein Matthew See Remarks Sell 558 $1.30 $725 126,491 −0.4% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.